Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

G. Allevi, C. Strina, D. Andreis, V. Zanoni, L. Bazzola, S. Bonardi, C. Foroni, M. Milani, M. R. Cappelletti, F. Gussago, S. Aguggini, R. Giardini, M. Martinotti, S. B. Fox, A. L. Harris, A. Bottini, A. Berruti, D. Generali

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution study comprised 120 oestrogen receptor (ER)-positive postmenopausal women with primary breast cancer (clinical stage ≥T2, N0-1), from three sequential cohorts (cohort A of 40, cohort B of 40 and cohort C of 40 patients, respectively) based on different duration of the neoadjuvant letrozole. Biological markers such as ER, progesterone receptor, HER2 and Ki-67 expression were tested at diagnosis and at definitive surgery.Results:A total of 89 patients (75.4%) achieved an objective response with 44 (37.3%) clinical CRs and 45 (38.1%) partial responses. The clinical CRs were significantly observed in cohort C (23 out of 40 patients, 57.5%) and B (16 out of 38 patients, 42.1%) compared with cohort A (5 out of 40 patients, 12.5%) (P-value for trend

Original languageEnglish
Pages (from-to)1587-1592
Number of pages6
JournalBritish Journal of Cancer
Volume108
Issue number8
DOIs
Publication statusPublished - Apr 30 2013

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer'. Together they form a unique fingerprint.

Cite this